Aguilar, Angelo
Thomas, Junius E.
Wang, Shaomeng
Funding for this research was provided by:
National Cancer Coalition (5R01CA219345)
Article History
Received: 3 May 2023
Accepted: 2 June 2023
First Online: 23 June 2023
Compliance with ethical standards
:
: SW and AA are co-inventors of an MDM2 inhibitor APG-115 and MDM2 degraders, which have been licensed by Ascentage Pharma Group for clinical development and they receive royalty from the University of Michigan. SW is a co-founder of Ascentage, owns stock in Ascentage and is a paid consultant of Ascentage. The University of Michigan also has a research contract with Ascentage.